



# NIH funding opportunities



Faculty of Medicine and Health Sciences: Research Development and Support 23 Oct 2017 (#38)

[Click on blue [hyperlink](#) for further information]

The NIH funding opportunities listed below are only a **selection** of pre-screened, currently open health funding opportunities for which **South African institutions are eligible to apply**. For a comprehensive selection of NIH funding opportunities, please visit [www.grants.nih.gov](http://www.grants.nih.gov).

Please be advised that you **must contact the Research Grants Management Office (RGMO) Pre-Awards** (Dr Christa de Vries [cdevries@sun.ac.za](mailto:cdevries@sun.ac.za)) to inform of your intent to apply.

**Timelines:** Confirm your intent to apply **as soon as possible, but not later than 30 days before the submission date**. All final documents **MUST reach the RGMO seven (7) workdays before NIH application due date**. The application will be submitted **four (4) workdays before the application due date**.

## 1. Maintaining Immunity After Immunization (Clinical Trial Optional)

**Letter of Intent:** 30 days prior to the application due date

**Hyperlink:** [\(RFA-AI-17-034\)](#)

**Type:** U01

**Application Due Date:** February 21, 2018. Apply by 5:00 PM local time of applicant organization.

**Funding Opportunity Announcement:** The goal of this Funding Opportunity Announcement (FOA) is to improve understanding of how durable protective immunity is achieved by supporting studies that define components and mechanisms of the immune system.

Applications proposing human cells/tissue response studies will help determine the human responses elicited by immunization, however, animal studies may also be used to extend the findings from human tissues to more mechanistic studies not easily accomplished in humans.

**Budget:** NIAID intends to commit \$6.4 M in FY 2019 to fund 7-10 awards. The budget is limited to \$450,000 in direct costs per year, and should reflect the actual needs of the project. The maximum project period is five years.

## 2. Building Research Capacity in Global Tobacco Product Regulation Program (FDA)

**Letter of Intent:** 30 days prior to the application due date

**Hyperlink:** [\(RFA-FD-18-003\)](#)

**Type:** U18

**Application Due Date:** December 18, 2017 by 11:59 PM Eastern Time.

**Funding Opportunity Announcement:** The Food and Drug Administration announces its intention to accept and consider a single source application for award to the World Health Organization (WHO) for the Building Research Capacity in Global Tobacco Product Regulation Program. The purpose of the Program is to identify, support, develop, conduct, and coordinate research efforts relating to tobacco control laws and rules in foreign countries that will directly inform and support FDA's exercise of its authority to regulate the manufacture, distribution, marketing and sale of tobacco products in the United States. The Program will advance FDA's Center for Tobacco Products' (CTP's) mission by utilizing the World Health Organization's (WHO) Member States' expertise and extensive international contacts in global tobacco control, as well as WHO's own programmatic expertise, to inform and support adequate manufacture, distribution and market regulations of tobacco products for the protection of public health in the United States. The Program will also provide a universal public benefit by creating opportunities for collaboration and research development globally, thereby resulting in better-informed and effective tobacco product regulation around the world, and increased knowledge in the public sphere regarding tobacco use and its harms globally.

**Budget:** The number of awards is contingent upon FDA appropriations and the submission of a sufficient number of meritorious applications. FDA/CTP intends to fund one (1) award up to \$450,000 for fiscal year 2018 in support of this cooperative agreement program (total costs including indirect costs for one award subject to availability of funds). FDA/CTP anticipates the possibility of four (4) additional years of support up to \$1,800,000 of funding contingent upon successful performance and the availability of funding. The scope of the proposed project should determine the project period. The maximum project period is Five (5) years.

### 3. Prevention and Treatment through a Comprehensive Care Continuum for HIV-affected Adolescents in Resource Constrained Settings (PATC3H)

**Letter of Intent:** 30 days prior to the application due date

**Hyperlink:** [\(RFA-HD-18-032\)](#)

**Type:** UG3/UH3

**Application Due Date:** December 22, 2017. Apply by 5:00 PM local time of applicant organization.

**Funding Opportunity Announcement:** The purpose of this FOA is to stimulate much needed research in an important area of public health significance: prevention of new HIV infections among adolescents at risk, and the identification of, linkage to and retention in care of, and long term viral suppression among youth living with HIV in low-to-middle income countries. These settings must have an HIV epidemic density defined by UNAIDS estimates as either a country 1) in which at least 200,000 people are living with HIV and the number has not decreased by more than 5% over the last 2 consecutive years of available data or 2) has an HIV prevalence of 3% or more. The UG3/UH3 Phased Innovation Awards Cooperative Agreement involves 2 phases. Funding for a UG3 phase will be used to demonstrate sufficient preparation, feasibility and capacity to meet foundational milestone targets specific to the work proposed. A UG3 project that meets its milestones will be administratively considered by NICHD and prioritized for transition to the UH3 award. Applicants responding to this FOA must address objectives for both the UG3 and UH3 phases.

**Budget:** NICHD and partner components intend to commit an estimated total of \$9,000,000 to fund approximately 8-9 awards for fiscal year 2018. Future year amounts will depend on annual appropriations. Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The project period may be up to 5 years: up to 2 years for the first phase (UG3) and up to 3 years for the second phase (UH3).

### 4. Investigator-Initiated Clinical Trials Targeting Diseases within the Mission of National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (Clinical Trial Required)

**Letter of Intent:** 30 days prior to the application due date

**Hyperlink:** [\(PA-18-330\)](#)

**Type:** R01

**Application Due Date:** [Standard dates](#) and [Standard AIDS dates](#) Apply by 5:00 PM local time of applicant organization.

**Funding Opportunity Announcement:** This Funding Opportunity Announcement (FOA) invites applications for investigator-initiated clinical trials within the mission of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) to be conducted at no more than two clinical research centers. NIDDK is committed to improving the health of people with diabetes and other endocrine and metabolic diseases; digestive diseases, nutritional disorders, and obesity; and kidney, urologic and hematologic diseases. Applications for clinical trials submitted under this FOA should be hypothesis driven, have clearly described aims and objectives, and have a high likelihood that the trial findings will improve understanding, diagnosis, prevention or treatment of the diseases studied and have the potential to impact clinical practice and/or public health.

**Budget:** The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications. Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is five years.

**Brief definitions of some NIH grant mechanisms:** [comprehensive list of extramural grant and cooperative agreement activity codes](#)

**R01 – NIH Research Project Grant Program:** most common NIH program; to support a discrete, specified, circumscribed research project; generally 3-5 years; budget may be specified, but generally <\$500,000 p.a. (direct costs).

**R21 – NIH Exploratory/Developmental Research Grant:** encourages new, exploratory and developmental research projects (could be used for pilot or feasibility studies); up to 2 years; budget total generally <\$275,000 (direct costs).

**R03 – NIH Small Grant Program:** limited funding for short period to support e.g. pilot / feasibility study, collection of preliminary data, secondary analysis of existing data, small-contained research projects, development of new research technology, etc.; normally for “new investigators”; not renewable; up to 2 years; budget generally <\$50,000 (direct costs).